This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BACE1 / Beta-secretase 1 · IHC design guide
Design Immunohistochemistry for BACE1
Plan BACE1 staining in paraffin sections using the observed granular cytoplasmic tissue pattern (HPA tissue IHC). This guide covers fixation, staining controls, and interpretation alongside BACE1’s trans-Golgi localization and membrane topology (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
BACE1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Granular cytoplasm (HPA tissue IHC); mainly trans-Golgi network (UniProt) | |
| Staining pattern | Granular cytoplasm; high in cerebellar GLUC cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A00322) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Formaldehyde-fixed human liver was used for IHC (datasheet A00322). (selected-SKU IHC image A00322) | |
| Caveat | Staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | No expression regulator specified (UniProt) | |
| Isoform / epitope | 6 isoforms; check whether the epitope lies in the ectodomain or cytoplasmic tail (UniProt) |
Section 1
Recommended BACE1 IHC & IF Protocols
The catalog antibody’s citrate pH 6 IHC-P protocol (datasheet A00322) is followed by four published BACE1 chromogenic IHC workflows (PMC4829010; PMC2970759; PMC6073981; PMC10969905).
| Sample | Formaldehyde-fixed, paraffin-embedded human liver tissue (datasheet A00322) |
| Fixation | Image formalin-fixed; duration unreported (datasheet A00322); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6 (datasheet A00322); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% serum (datasheet A00322) |
| Primary antibody | Rabbit anti-BACE1, 1-2 μg/mL (datasheet A00322) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | BACE1-positive staining in gLUC cells - cytoplasm/membrane of cerebellum (HPA tissue IHC: High). HPA tissue profile: Granular cytoplasmic expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate pH 6 retrieval for paraffin sections (datasheet A00322; PMC10969905); the formamide retrieval conditions were reported for other section preparations (PMC4829010; PMC2970759).
Section 2
What Is the Expected BACE1 Staining Pattern?
In paraffin-section IHC, expect granular cytoplasmic staining in selected neural cells, with possible membrane-associated signal (HPA tissue IHC: granular cytoplasmic expression; UniProt P56817: membrane and intracellular locations). BACE1 has an extracellular region, one transmembrane segment and a short cytoplasmic tail (UniProt P56817 topology). HPA rates its tissue IHC evidence Approved while reporting low consistency between antibody staining and RNA expression (HPA tissue IHC: reliability). Interpret staining with that limitation in mind.
| Granular cytoplasmic staining in cerebellar GLUC cells; staining in cortical neurons or caudate glia. | This fits the reported tissue pattern: cerebellar GLUC cells are High, while cortical neuronal cells and caudate glial cells are Medium (HPA tissue IHC). Golgi and endosomal localization also supports intracellular signal (UniProt P56817 subcellular location). |
| Predominantly nuclear staining, with little granular cytoplasmic signal in expected positive cells. | A nuclear-dominant pattern is discordant with the reported granular cytoplasmic IHC and membrane-associated localization (HPA tissue IHC; UniProt P56817 subcellular location). Treat it as suspect; morphology alone cannot establish the cause. |
| Strong staining in adipocytes, cervical squamous epithelium or salivary glandular cells. | These cell types are reported Not detected (HPA tissue IHC). Check for nonspecific antibody binding or endogenous chromogenic activity (general IHC practice), particularly if expected positive cells on the same run stain poorly. |
| Uniform color across cells and extracellular spaces, obscuring granules and cell boundaries. | That distribution is difficult to reconcile with granular cytoplasmic expression (HPA tissue IHC). Consider background from antibody concentration, blocking, washing or detection chemistry (general IHC practice); do not score haze as cellular positivity. |
| No staining in cerebellar GLUC cells or cortical neurons, despite interpretable tissue morphology. | These are reported High and Medium, respectively (HPA tissue IHC). A blank result raises a run-performance concern, but HPA’s low staining-to-RNA consistency limits conclusions about any individual specimen (HPA tissue IHC: reliability). |
💡Expected BACE1 appearanceCall positive a granular cytoplasmic signal in cerebellar GLUC cells (High) or cortical neurons and caudate glia (Medium); diffuse haze or nuclear-dominant color alone is suspect (HPA tissue IHC; UniProt P56817 subcellular location).
| Which compartment should guide scoring? | HPA describes granular cytoplasmic tissue IHC, while UniProt places BACE1 predominantly in the later Golgi/trans-Golgi network and also in endosomes and at the cell surface (HPA tissue IHC; UniProt P56817 subcellular location). Score the observed cell pattern, not an assumed single organelle. |
| Does epitope position matter? | The mature chain spans residues 46–501; residues 22–457 are extracellular and 479–501 cytoplasmic across a 458–478 transmembrane segment (UniProt P56817 processing and topology). The antibody epitope is unspecified here, so this record cannot predict its accessibility or an optimal retrieval condition. |
| Can processing or isoforms change interpretation? | UniProt lists a cleaved signal peptide, a propeptide and 6 isoforms (UniProt P56817 processing and isoforms). Antibody recognition across those forms is unspecified; neither altered staining nor a particular staining intensity can be assigned to one form from morphology alone. |
| How strong is antibody support? | CAB016358 is Approved for IHC and Supported for ICC, while tissue IHC has low consistency with RNA expression (HPA antibody validation; HPA tissue IHC: reliability). Use the tissue examples as guides, not guarantees for every specimen or proof of antibody specificity. |
| What does retrieval establish? | Antigen retrieval is a routine paraffin IHC variable (general IHC practice). No target-specific fixation or retrieval response is supplied for BACE1, so optimize and document the chosen condition against positive and negative tissue controls without claiming a predicted gain. |
| IF/ICC Q: Should plasma-membrane staining be expected? | A: Plasma membrane is the supported main ICC-IF location, with images listed for A-431 and U-251MG (HPA subcellular ICC-IF). That observation informs localization but does not replace the granular cytoplasmic pattern reported for tissue IHC (HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| The known-positive tissue is blank. | The reported High cerebellar GLUC-cell or Medium cortical neuronal signal is absent (HPA tissue IHC); a failed detection step or unsuitable working conditions are possible (general IHC practice). | Verify tissue preservation and run controls, then review retrieval, primary-antibody application and chromogen development in that order (general IHC practice). Recheck a second reported positive tissue before calling a specimen negative (HPA tissue IHC). |
| Background covers most of the section. | Diffuse signal does not match granular cytoplasmic expression (HPA tissue IHC). Excess primary or detection reagent, inadequate blocking or insufficient washes can produce background (general IHC practice). | Compare a no-primary control, strengthen appropriate blocking and washing, and titrate the primary and detection reagents (general IHC practice). Judge improvement by recovery of discrete cellular granules (HPA tissue IHC). |
| Color appears in negative control cell types. | Adipocytes, cervical squamous cells and salivary glandular cells are reported Not detected (HPA tissue IHC); nonspecific binding or endogenous chromogenic activity may account for color (general IHC practice). | Check no-primary and detection-only controls, suppress endogenous enzyme activity when applicable, and compare the suspect cells with a reported positive tissue (general IHC practice; HPA tissue IHC). |
| Nuclei dominate the stain. | Nuclear-dominant staining conflicts with HPA’s granular cytoplasmic tissue pattern and UniProt’s membrane and organelle locations (HPA tissue IHC; UniProt P56817 subcellular location). | Review counterstain and chromogen separately, inspect a no-primary control and reassess whether positive cells also show the expected cytoplasmic granules (general IHC practice; HPA tissue IHC). |
| Only a thin cell-edge signal is visible. | Cell-surface localization is possible (UniProt P56817 subcellular location), but HPA’s tissue IHC profile emphasizes granular cytoplasm (HPA tissue IHC). Edge staining alone leaves the tissue interpretation uncertain. | Inspect a reported positive cell population for intracellular granules and compare a negative cell population on the same run; avoid scoring edge-only staining as definitive BACE1 positivity (HPA tissue IHC). |
| A specimen disagrees with an RNA-based expectation. | HPA explicitly reports low consistency between antibody staining and RNA expression, despite its Approved tissue IHC rating (HPA tissue IHC: reliability). RNA enrichment in brain and pancreas does not specify staining in every cell (HPA tissue IHC: RNA specificity). | Record the actual stained cell type, compartment and intensity; compare them with HPA’s cell-specific IHC examples and controls before interpreting the discrepancy (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing BACE1 staining
A00322 · IHCImmunohistochemistry Validation of BACE in Human Liver Immunohistochemical analysis of paraffin-embedded human liver tissue using anti-BACE
A00322 · IHCKD Validation of BACE in Mouse Brain (Singer et al., 2005) Characterization of the effects of lenti-siBACE1-6 expression in the brains of AP
A00322 · IFImmunofluorescence Validation of BACE in Mouse Liver Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse liver tissue labeling BAC
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000186318-BACE1/tissue/cerebral+cortex#imid_4031604
HPA · HippocampusHuman Protein Atlas IHC, Hippocampus. Source: https://www.proteinatlas.org/ENSG00000186318-BACE1/tissue/hippocampal+formation#imid_4031613
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000186318-BACE1/tissue/colon#imid_4031530
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000186318-BACE1/tissue/liver#imid_4031547
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB016358; green = BACE1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB016358; green = BACE1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for BACE1 IHC & IF
🧪Run cerebellum first and confirm staining in GLUC cell cytoplasm or membrane (HPA: High in cerebellar GLUC cells). Use adipose tissue as a negative comparator (HPA: Not detected in adipocytes); other cells on the cerebellar slide should be assessed for background rather than assumed to be BACE1-negative (HPA: cerebellar staining specified for GLUC cells).
Positive control tissue: Cerebellum (GLUC cells - cytoplasm/membrane, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BACE1 in A-431, U-251MG, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-species- and clonality-matched isotype controls, plus BACE1-knockout tissue or a peptide-blocking control if the immunizing peptide is available (standard IHC practice). Quench endogenous peroxidase for chromogenic detection; if assessing cerebellum by IF, check tissue autofluorescence with an unstained control (standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A00322 caption metadata lists the fixative as unreported (selected A00322 caption metadata: fixative not stated). Heat retrieval with citrate buffer at pH 6 is documented for the catalog antibody’s paraffin-section image, but its necessity has not been established by the supplied evidence (A00322 tissue-IHC caption: heat retrieval with citrate buffer, pH 6). Frozen sections and IF cannot be assumed easier from these data; cerebellar autofluorescence requires a background check if IF is used (HPA: High in cerebellar GLUC cells; standard IF practice).
HPA tissue IHC evidence for BACE1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | GLUC cells - cytoplasm/membrane | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Caudate | Glial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Cervix | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Ovary | Ovarian stroma cells | Not detected | Protein (IHC) | HPA → |
| Salivary gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced BACE1 IHC Tips
Use matched controls and compartment-aware scoring when troubleshooting chromogenic BACE1 IHC in paraffin sections.
How should I troubleshoot weak BACE1 staining after antigen retrieval?
Start with heat-mediated retrieval in citrate buffer at pH 6 for paraffin sections (datasheet A00322). The selected tissue image used this retrieval with catalog antibody A00322 at 2 µg/ml (A00322 tissue-IHC caption). If signal is weak, compare retrieval heating and cooling conditions on adjacent sections while keeping antibody concentration and chromogenic development constant (standard IHC practice). Include a positive tissue control and a no-primary control so improved staining can be distinguished from increased background (standard IHC practice). Record whether any gain appears in the expected granular cytoplasm or membrane-associated compartments (HPA: tissue IHC profile; UniProt P56817 localisation).
Could fixation explain weak or uneven BACE1 staining?
Target-specific sensitivity of BACE1 staining to fixation is unknown from the supplied evidence; do not infer it from tissue patterns or protein topology. For paraffin IHC, document fixative, fixation duration, section thickness and processing history before comparing specimens (standard IHC practice). Test adjacent sections with the same pH 6 citrate retrieval and antibody conditions to isolate processing-related differences (datasheet A00322; standard IHC practice). Check whether staining loss tracks section edges, folds or poorly preserved areas, and compare with a preserved positive-control section (standard IHC practice). Report fixation differences as a possible technical variable until matched material confirms their effect on the assay (standard IHC practice).
Where should convincing BACE1 staining appear in tissue sections?
Evaluate granular cytoplasmic staining and cell-associated membrane staining in paraffin sections (HPA: tissue IHC profile; HPA: cerebellar GLUC cells). BACE1 is predominantly associated with later Golgi and trans-Golgi compartments, with smaller pools in endosomes and at the cell surface (UniProt P56817 localisation). A plasma-membrane location is also supported by cellular imaging (HPA: subcellular summary). Use the section’s morphology and a matched positive control to decide whether puncta lie within cells rather than over tissue debris (standard IHC practice). Do not require every positive cell to show a continuous surface rim, because the recorded distribution spans intracellular compartments (UniProt P56817 localisation).
Can an antibody epitope explain differing BACE1 IHC patterns?
Check the catalog antibody’s immunogen or mapped epitope before attributing staining differences to a BACE1 isoform (standard IHC practice). The record lists 6 isoforms and a precursor with signal peptide residues 1–21 and propeptide residues 22–45 (UniProt P56817 processing; isoforms). The mature chain begins at residue 46, and the transmembrane segment spans residues 458–478 (UniProt P56817 processing; topology). Four recorded glycosylation sites occur at residues 153, 172, 223 and 354 (UniProt P56817 glycosylation). Without an epitope map and isoform-specific validation, score the observed staining as antibody reactivity rather than assigning it to a particular isoform (standard IHC practice).
How can I investigate a BACE1 IHC pattern with multiplex IF?
Use multiplex IF as a follow-up to localise cells contributing to the chromogenic signal, with controls appropriate to the IF assay (standard IHC/IF practice). Pair BACE1 with a marker of the expected cell type, such as a neuronal marker when investigating cerebral-cortex neuronal staining (HPA: cerebral cortex neuronal cells). Choose spectrally separated fluorophores and inspect unstained tissue for autofluorescence before assigning puncta to BACE1 (standard IF practice). Select permeabilisation according to the antibody’s mapped epitope: residues 22–457 are extracellular or luminal, whereas residues 479–501 are cytoplasmic (UniProt P56817 topology). Verify the IF staining independently; chromogenic tissue validation does not establish this catalog antibody’s IF performance (standard assay-validation practice).
What should I check when BACE1 DAB staining is widespread?
Run a no-primary control through the same secondary antibody and DAB steps to identify background from detection reagents or endogenous enzyme activity (standard chromogenic IHC practice). Include a peroxidase-blocking step and assess its effect with the same development time across sections (standard chromogenic IHC practice). The selected image used 10% serum blocking for 1 hour at room temperature and an HRP secondary at 1:250 (A00322 tissue-IHC caption). Compare candidate background with HPA’s granular cytoplasmic pattern and its reported unstained cell populations (HPA: tissue IHC profile). If background persists, review blocking, washes, secondary specificity and DAB development before increasing primary antibody concentration (standard IHC practice).
How should I quantify BACE1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue area before scoring, then apply one staining threshold and imaging setup across the comparison (standard IHC quantification practice). Report the percentage of positive cells and an intensity-weighted H-score of 0–300, or count positive cells per mm² when density is the outcome (standard IHC quantification practice). Normalise cell counts to evaluable tissue area and compare intensity within the same cell type rather than across changing tissue composition (standard IHC quantification practice). Exclude folds, section edges and necrotic areas using a prespecified rule (standard IHC quantification practice). Record the compartment scored, because BACE1 staining can include granular cytoplasm and membrane-associated signal (HPA: tissue IHC profile; UniProt P56817 localisation).
How can I distinguish true BACE1 staining from artefact?
First ask whether staining is cell-associated and compatible with granular cytoplasm or membrane-associated compartments (HPA: tissue IHC profile; UniProt P56817 localisation). Compare the stained cell population with a positive control; HPA reports neuronal cells in cerebral cortex and glial cells in caudate at medium levels (HPA: tissue IHC). Treat signal confined to section edges, folds or necrotic material as suspect, and inspect the no-primary control for residual enzyme-associated DAB (standard chromogenic IHC practice). HPA describes its tissue staining as approved but notes low consistency with RNA expression data (HPA: tissue IHC reliability). Interpret an unexpected pattern provisionally until independent controls support its cellular location and specificity (standard IHC practice).
Boster reagents
Best BACE1 / Beta-secretase 1 IHC Antibodies
The IHC-validated BACE1 antibody A00322 has paraffin-section IHC data from human liver and IF data from mouse liver (IHC and IF image captions).
Real IHC data
Anti-BACE BACE1 Antibody
Cat # A00322
A00322 is listed for IHC-P and IF, with human IHC and mouse IF validation (catalog applications; catalog validation note). Its images show formaldehyde-fixed, paraffin-embedded human liver IHC and 4% paraformaldehyde-fixed mouse liver IF (IHC and IF image captions).
Which to pick: For tissue IHC, choose A00322; its human liver image documents paraffin sections, formaldehyde fixation and heat retrieval in citrate buffer at pH 6 (IHC image caption). For IF, A00322 has mouse liver data; ICC validation is unreported (IF image caption; catalog validation note). For work spanning human and mouse samples, A00322 is a rabbit polyclonal with both species listed as reactive, while its documented IHC validation is human and IF validation is mouse (catalog host, clonality and reactivity; catalog validation note).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P56817 (BACE1_HUMAN, Beta-secretase 1).
- Human Protein Atlas. BACE1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. BACE1 subcellular location (ICC-IF): Localized to the plasma membrane..
- Human Protein Atlas. BACE1 antibody validation summary (1 antibodies).
- BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer's disease. Neural regeneration research 2016 — PMC4829010.
- β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation. The European journal of neuroscience 2010 — PMC2970759.
- BACE1 Regulates Proliferation and Neuronal Differentiation of Newborn Cells in the Adult Hippocampus in Mice. eNeuro 2018 — PMC6073981.
- Identification and Analysis of Axolotl Homologs for Proteins Implicated in Human Neurodegenerative Proteinopathies. Genes 2024 — PMC10969905.
- PubMed PMID:10531052 — UniProt-cited evidence.
- PubMed PMID:10591214 — UniProt-cited evidence.
- PubMed PMID:10591213 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for BACE1 (Beta-secretase 1). Expected localisation Granular cytoplasm (HPA tissue IHC); mainly trans-Golgi network (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A00322). Validated IHC antibody: A00322 at 1-2 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (GLUC cells - cytoplasm/membrane); negative Adipose tissue. IHC-P workflow on paraffin sections. Protocol steps: 1. Sample: Formaldehyde-fixed, paraffin-embedded human liver tissue (datasheet A00322); 2. Fixation: Image formalin-fixed; duration unreported (datasheet A00322); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 (datasheet A00322); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% serum (datasheet A00322); 8. Primary antibody: Rabbit anti-BACE1, 1-2 μg/mL (datasheet A00322); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Formaldehyde-fixed human liver was used for IHC (datasheet A00322). (selected-SKU IHC image A00322); Caveat: Staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 6 isoforms; check whether the epitope lies in the ectodomain or cytoplasmic tail (UniProt); Regulation: No expression regulator specified (UniProt). Evidence: UniProt P56817, HPA tissue IHC · Approved, HPA ICC-IF · plasma membrane., Datasheet A00322, PMC4829010, PMC2970759. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/BACE1/immunohistochemistry-ihc-guide.